SEARCH:   Advanced

Prepublished online as a Blood First Edition Paper on January 30, 2003; DOI 10.1182/blood-2002-10-3188. This Article Full Text (PDF) All Versions of this Article: 2002-10-3188v1 101/11/4387    most recent Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Rights and Permissions Citing Articles Citing Articles via HighWire Citing Articles via CrossRef Citing Articles via Google Scholar Google Scholar Articles by Dahm, A. Articles by Sandset, P. M. Search for Related Content PubMed PubMed Citation Articles by Dahm, A. Articles by Sandset, P. M. Related Collections Related Article in Blood Online Social Bookmarking                   What's this? Submitted October 23, 2002 Accepted January 20, 2003 Low levels of tissue factor pathway inhibitor (TFPI) increase the risk of venous thrombosis Anders Dahm*, Astrid van Hylckama Vlieg, Bjorn Bendz, Frits Rosendaal, Rogier M Bertina, and Per Morten Sandset Department of Hematology, Ullevaal University Hospital, Oslo, Norway Department of Clinical Epidemiology and Department of Hematology, Leiden University Medical Center, Leiden, The Netherlands * Corresponding author; email: a.e.a.dahm{at}klinmed.uio.no. There is now strong experimental evidence that tissue factor pathway inhibitor (TFPI) is a critical inhibitor to modulate tissue factor induced coagulation, but the role of TFPI as a risk factor for thrombosis is yet to be to be determined. This study investigated the role of low TFPI levels for the development of deep vein thrombosis (DVT). We determined TFPI activity and TFPI free and total antigen levels in the subjects enrolled in the Leiden Thrombophilia Study, which is a large population-based case-control study of 474 patients and 474 controls. The odds ratio (OR) for DVT in subjects who had TFPI free antigen levels below the 10th percentile in the controls, as compared with those who had TFPI free antigen levels above this cut-off, was 1.7 (95% confidence interval [CI], 1.1-2.6). The ORs for low TFPI activity and low total antigen were also mildly increased. Using the 5th percentile as a cut-off, the ORs were 2.1 (95% CI 1.1-4.1) for both TFPI free and total antigen. Exogenous female hormones had a profound lowering effect on TFPI levels with lower levels in oral contraceptive (OC) users than in premenopausal non-users, who again had lower levels than postmenopausal women and men. These results indicate that low levels of TFPI, especially low TFPI free and total antigen in plasma, is a risk factor for DVT. CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this? Related Article in Blood Online: TFPI and venous thrombosis Kenneth A. Bauer Blood 2003 101: 4228-4229. [Full Text] [PDF] This article has been cited by other articles: C. Duckers, P. Simioni, L. Spiezia, C. Radu, S. Gavasso, J. Rosing, and E. Castoldi Low plasma levels of tissue factor pathway inhibitor in patients with congenital factor V deficiency Blood, November 1, 2008; 112(9): 3615 - 3623. [Abstract] [Full Text] [PDF] J. T.B. Crawley and D. A. Lane The Haemostatic Role of Tissue Factor Pathway Inhibitor Arterioscler Thromb Vasc Biol, February 1, 2008; 28(2): 233 - 242. [Abstract] [Full Text] [PDF] S. O. Skouby, J. J. Sidelmann, L. Nilas, and J. Jespersen A comparative study of the effect of continuous combined conjugated equine estrogen plus medroxyprogesterone acetate and tibolone on blood coagulability Hum. Reprod., April 1, 2007; 22(4): 1186 - 1191. [Abstract] [Full Text] [PDF] H. F.S. Negaard, A. L. Eilertsen, A. Dahm, P. O. Iversen, B. Ostenstad, and P. M. Sandset Decreased Lung Cancer Survival With Hormone-Replacement Therapy: Caused by a Decreased Tissue Factor Pathway Inhibitor Level? J. Clin. Oncol., June 10, 2006; 24(17): 2683 - 2684. [Full Text] [PDF] T. M. Hackeng, K. M. Sere, G. Tans, and J. Rosing Protein S stimulates inhibition of the tissue factor pathway by tissue factor pathway inhibitor PNAS, February 28, 2006; 103(9): 3106 - 3111. [Abstract] [Full Text] [PDF] M. Pinotti, C. Bertolucci, F. Portaluppi, I. Colognesi, E. Frigato, A. Foa, and F. Bernardi Daily and Circadian Rhythms of Tissue Factor Pathway Inhibitor and Factor VII Activity Arterioscler Thromb Vasc Biol, March 1, 2005; 25(3): 646 - 649. [Abstract] [Full Text] [PDF] A. E.A. Dahm, T. O. Andersen, F. Rosendaal, and P. M. Sandset Biological Relevance of a New TFPI Anticoagulant Activity Assay of Full-Length TFPI. Blood (ASH Annual Meeting Abstracts), November 16, 2004; 104(11): 2982 - 2982. [Abstract] M. Erman, H. Abali, B. Oran, I. C. Haznedaroglu, H. Canpinar, S. Kirazli, and I. Celik Tamoxifen-induced tissue factor pathway inhibitor reduction: a clue for an acquired thrombophilic state? Ann. Onc., November 1, 2004; 15(11): 1622 - 1626. [Abstract] [Full Text] [PDF] T. E. Warkentin, W. C. Aird, and J. H. Rand Platelet-Endothelial Interactions: Sepsis, HIT, and Antiphospholipid Syndrome Hematology, January 1, 2003; 2003(1): 497 - 519. [Abstract] [Full Text] [PDF]

	Copyright © 2003 by American Society of Hematology         Online ISSN: 1528-0020